Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study-Reference-Cited by-同舟云学术

Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study

Published:2024-04-10 Issue:1 Volume:27 Page:596-604
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Lau Edmund¹,Kotlyar Eugene²,Makanji Yogeshwar³^ORCID,Yu Dae Young³,Tan Jin Yu³,Casorso Jeremy⁴,Kouhkamari Mahsa H.⁴,Lim Sooyeol⁴,Wu David Bin-Chia³⁵^ORCID,Bloomfield Paul³

Affiliation:

1. Royal Prince Alfred Hospital, University of Sydney, Camperdown, Australia

2. St. Vincent’s Hospital, Sydney, Australia

3. Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore

4. Prospection, Haymarket, Australia

5. Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

Funder

Janssen Asia Pacific Medical Affairs

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2024.2328483

Reference28 articles.

1. Treatment of Pulmonary Arterial Hypertension

2. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort

3. The Pharmaceutical Benefits Scheme. Pulmonary arterial hypertension (PAH) medicines utilisation analysis. Sydney Australia: The Pharmaceutical Benefits Scheme Drug Utilisation Sub-committee; 2015. [cited 2023 May 19]. Available from: http://www.pbs.gov.au/industry/listing/participants/public-release-docs/pulm-art-hypertension/pulmonary-arterial-hypertension-dusc-prd-2015-02-final.pdf.

4. Pharmacological Treatment of Pulmonary Arterial Hypertension in Australia: Current Trends and Challenges

5. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension